Elzovantinib

N/A

Report date: 2022/05/30 20:00:35
NME

Base Information

Drug NameElzovantinib
Drug Alias NameTPX-0022
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsColony stimulating factor 1 receptor inhibitorsTyrosine-protein kinase SRC inhibitors
TargetsColony stimulating factor 1 receptorHepatocyte growth factor receptorTyrosine-protein kinase SRC
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceSpain +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTurning Point Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesZai Lab (Shanghai) Co LtdTurning Point Therapeutics IncPatheon Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A